This study found that CD30+EV could bind not only to DLBCL cell lines but also to fluorescein-labeled BV, creating conditions for BV to kill CD30-tumor cells, and both confocal microscopy and FCM showed that the binding and uptake of BV depended on CD30+EV, so only in the presence of CD30+EV can BV kill CD30-tumor cells (102). This evidence concerns the gene TNFRSF8 and neoplasm.